Familial LCAT deficiency: From renal replacement to enzyme replacement

Netherlands Journal of Medicine

Volumn 71, Issue 1, 2013, Pages 29-31

  Stoekenbroek, R M ^a   van den Bergh Weerman, M A ^a   Hovingh, G K ^a   Potter van Loon, B J ^b   Siegert, C E H ^b   Holleboom, A G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Familial LCAT deficiency; FLD; LCAT; Renal failure

Indexed keywords

APOLIPOPROTEIN A1; CANDESARTAN; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; QUINAPRIL;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; ELECTRON MICROSCOPY; ENZYME REPLACEMENT; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; KIDNEY BIOPSY; KIDNEY FAILURE; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LUNG EDEMA; MALE; MICROCYTIC ANEMIA; PROTEINURIA; RENAL REPLACEMENT THERAPY;

ADULT; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; HUMANS; KIDNEY FAILURE, CHRONIC; LECITHIN ACYLTRANSFERASE DEFICIENCY; MALE; MIDDLE AGED; PEDIGREE; RENAL REPLACEMENT THERAPY;

EID: 84874169331     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Holleboom AG, Kuivenhoven JA, van Olden CC, et al. Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase. Atherosclerosis. 2011;216:161-5.
2. Lewis G, Rader D. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-32.
3. Holleboom AG, Kuivenhoven JA, Peelman F, et al. High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in the Netherlands: Identifi{ligature}cation and characterization of eight novel mutations. Hum Mutat. 2011;32:1-9.
4. Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer HB Jr. Lecithin cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. 2000;11:267-75.
5. http://www.alphacorepharma.com/wp-content/uploads/2012/02/ ACP-ABL-press-release-final.pdf. Internet source.
6. Fröhlich J, McLeod R, Pritchard PH, Fesmire J, McConathy W. Plasma lipoprotein abnormalities in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency. Metabolism. 1988;37:3-8.
7. Funke H, von Eckardstein A, Pritchard PH. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified alleles further contribute to the structural heterogeneity in this disease. J Clin Invest. 1993;91:677-83.
8. Human Gene Mutation Database. Human Gene Mutation Database. 2010. Ref Type: Internet Communication.
9. Imbasciati E, Paties C, Scarpioni L, Mihatsch MJ. Renal lesions in familial lecithin-cholesterol acyltransferase deficiency: ultrastructural examination of glomerular changes. Am J Nephrol. 1986;6:66-70.
10. Jonas A. Regulation of lecithin cholesterol acyltransferase activity. Prog Lipid Res. 1998;37:209-4.
11. Aranda P, Valdivielso P, Pisciotta L, et al. Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). Clin Nephrol. 2008;69:213-8.
12. Miarka P, Idzior-Walús B, Kúzniewski M, Walús-Miarka M, Klupa T, Sutowicz W. Corticosid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency. Clin Exp Nephrol. 2011;15:424-9.
13. Panescu V, Grignon Y, Hestin D, et al. Recurrence of lecithin cholesterol acyltransferase deficiency after kidney transplantation. Nephrol Dial Transplant. 1997;12:2430-2.
14. Kuroda M, Aoyagi Y, Asada S, et al. Ceiling Culture-Derived Proliferative Adipocytes are A Possible Delivery Vehicle for Enzyme Replacement Therapy in Lecithin: Cholesterol Acyltransferase Deficiency. Open Gene Ther J. 2011;4:1-10.
15. Rousset X, Vaisman B, Auerbach B, et al. Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther. 2010;335:140-8.